🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

How familiar are you with the SEATTLE procedure? Learn how to deal with atrial tumors with a completely percutaneous procedure in #JACCCaseReports: bit.ly/3yYtW6B #cvSurg #CardioTwitter #CathLab Jamie McCabe

Fascinating discussion on the heart brain axis and #CMR beyond CVD #SCMR24 Society for Cardiovascular Magnetic Resonance 🧲🧠 Beautiful review of the blood-brain barrier and peri vascular space including effects of sleep deprivation 😴 Meng Law Jadranka Stojanovska MD MS FSCMR Albert Hsiao 蕭, MD, PhD, FNASCI, FSCMR, FAHA 🐳 Jordi Broncano Elsie Nguyen

How many medical conferences have childcare? Amazing Society for Cardiovascular Magnetic Resonance 👍🏻🙌 #MedTwitter #CardioTwitter #CMR2024

Presented at #CMR2024 & simultaneously published in European Society of Cardiology EHJ- academic.oup.com/eurheartj/adva… Our work BSCMR led by George Thornton Thomas Treibel Anvesha Singh we show that cmr myocardial Fibrosis predicts outcomes in Aortic Stenosis 10 years out! Mamas A. Mamas Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

Thanks to all those who have supported me in this honor and journey for #whyCMR Rob Gropler, Pamela Woodard, MD Douglas L Mann Tim Bateman Randall Thompson Iain McGhie C Bucciarelli-Ducci Karen Ordovas Christopher O'Connor Ketan Trivedi

#CMR2024 Drs Gerry McCann & Aparna Deshpande discussing Clinical Collaboration (Radiology/Cardiology) and the Growth in the UK. Thomas Treibel Jadranka Stojanovska MD MS FSCMR Robin Nijveldt Karen Ordovas EACVI President ESCR Vienna Society for Cardiovascular Magnetic Resonance European Society of Cardiology

🧲Everyone needs an Ariel #WhyCMR phantom 🔥🤖. Fantastic innovations presented by Gabriella Captur #CMR2024

Congratulations to Jadranka Stojanovska MD MS FSCMR and Thomas Treibel on a very successful #CMR2024 Few unique aspects of this meeting- 🧲 first ever collaboration between SCMR/ ESCVI/ ESCR #CardsRads 🧲 record attendance- 1300 new attendees compared to the last meeting 🧲 excellent

#CMR2024 takeaways🥡🍔: 🧲Quant perfusion🔥.🧲Need pulse sequence translation & consensus >perfection.🧲🤖 rising - AI acquistn, recon & processing; and robotic MR-steered RHC🔥.🧲#WhyCMR future bright with early career leaders, young scientists🌟 🧲 P/CHD innovations & growth📈

Exciting insights from our BSCMR Valve Consortium, presented at #CMR2024 and featured in #EHJ: In severe AS, myocardial scar detected by #whyCMR pre-operatively is linked to long-term survival post-AVR. This underscores theimportance of fibrosis for post-op risk stratification.

Plumber vs Plumber, will the cath or the scope prevail? DocSchmidt. Does this sound familiar ?!

Have you read our 2024 #guideline, "Guidelines for the Evaluation of Prosthetic Valve Function With Cardiovascular Imaging?" Check it out: bit.ly/3vosxI5 It was made in collaboration with Society for Cardiovascular Magnetic Resonance and the Heart_SCCT! #ValveDiseaseDay #valvedisease

🚨 COVID Heart 🚨 Myocardial injury in severe hospitalized COVID-19 survivors is nonprogressive with low incidence of MACE and improved quality of life. #WhyCMR #COVID19 🧵1/6 JACC Journals sciencedirect.com/science/articl…

The BSCMR 19th Annual conference begins. Thanks to Saul for a brilliant opening to the conference!

Prof Guy Lloyd teaching a fully packed room of cardiac physiologists and nurse specialists core clinical skills in our Valve Clinic teaching session for Audit Day. Invaluable! BartsEcho Guy Lloyd Thomas Treibel #valvularheartdisease #valve

Do you know the reduction of LV mass after AVR will be driven by "cellular compartment regression" or "extracellular regression"? Check out the new article in CircImaging below! #AHAJournals Jiwon Kim, MD Kaz Negishi@Cardiologist/ Heart Mafia ahajrnls.org/3BGPPfD

1/3_📢 Excited to see the results of our transatlantic registry published in #EHJ. Patients with both aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR-CA)—a group with unclear optimal management. Can AVR and tafamidis improve survival? 📄doi.org/10.1093/eurhea…

2/3_👥 N=226 (mean age 85) 🔹 71% had AVR (mostly TAVI) 🔹 32% received tafamidis 🔍 Results: Both AVR and tafamidis independently ↓ mortality Dual therapy (AVR + tafamidis) = best outcomes Survival similar to patients with lone AS undergoing AVR #EHJ #ValveDisease Christian Nitsche

3/3_🧠 Implication: Dual pathology (AS + ATTR-CA) should not preclude intervention. Combined AVR and disease-modifying therapy may restore prognosis. Non-randomised, but compelling signal for integrated treatment. @EurHeartJ #TAVR #Amyloidosis joao cavalcante Marco Merlo